Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6.

Choudhury AD, Schinzel AC, Cotter MB, Lis RT, Labella K, Lock YJ, Izzo F, Guney I, Bowden M, Li YY, Patel J, Hartman E, Carr SA, Schenone M, Jaffe JD, Kantoff PW, Hammerman PS, Hahn WC.

Cancer Res. 2017 Feb 1;77(3):753-765. doi: 10.1158/0008-5472.CAN-16-0455.

PMID:
27899381
2.

A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.

McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME.

Clin Cancer Res. 2017 Feb 15;23(4):935-945. doi: 10.1158/1078-0432.CCR-16-0987.

PMID:
27683182
3.

ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.

Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, McAllister G, Hoffman G, Ramadan N, Hartung A, Feng Y, Kipp DR, Quinn C, Fodor M, Baird J, Schoumacher M, Meyer R, Deeds J, Buchwalter G, Stams T, Keen N, Sellers WR, Brown M, Pagliarini RA.

Elife. 2016 May 16;5. pii: e13964. doi: 10.7554/eLife.13964.

4.

Androgen receptor regulates SRC expression through microRNA-203.

Siu MK, Chen WY, Tsai HY, Yeh HL, Yin JJ, Liu SY, Liu YN.

Oncotarget. 2016 May 3;7(18):25726-41. doi: 10.18632/oncotarget.8366.

5.

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW.

Nat Med. 2016 May;22(5):488-96. doi: 10.1038/nm.4070.

6.

Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.

Izumi K, Li L, Chang C.

Clin Investig (Lond). 2014 Oct 1;4(10):935-950.

7.

Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.

Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group..

EBioMedicine. 2015 Jul 29;2(9):1133-44. doi: 10.1016/j.ebiom.2015.07.017.

8.

Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass.

Yang CC, Fazli L, Loguercio S, Zharkikh I, Aza-Blanc P, Gleave ME, Wolf DA.

Oncotarget. 2015 Sep 8;6(26):22060-71.

9.

Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis.

Liu YN, Yin J, Barrett B, Sheppard-Tillman H, Li D, Casey OM, Fang L, Hynes PG, Ameri AH, Kelly K.

Mol Cell Biol. 2015 Jun 1;35(11):1940-51. doi: 10.1128/MCB.00008-15.

10.

Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.

Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin ME, Taub JM, Herman B, Higano CS, Doot RK, Hartfeil D, Febbo PG, Mankoff DA.

J Nucl Med. 2015 Mar;56(3):354-60. doi: 10.2967/jnumed.114.146936.

11.

Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells.

Jurmeister S, Ramos-Montoya A, Neal DE, Fryer LG.

Oncotarget. 2014 Jun 15;5(11):3785-99.

12.

AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.

Yin J, Liu YN, Tillman H, Barrett B, Hewitt S, Ylaya K, Fang L, Lake R, Corey E, Morrissey C, Vessella R, Kelly K.

Cancer Res. 2014 Aug 15;74(16):4306-17. doi: 10.1158/0008-5472.CAN-13-3233.

13.
14.

Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.

Chen Y, Chen J, Yu J, Yang G, Temple E, Harbinski F, Gao H, Wilson C, Pagliarini R, Zhou W.

J Biol Chem. 2014 Jul 4;289(27):18914-27. doi: 10.1074/jbc.M114.574053.

15.

A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.

Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ.

Invest New Drugs. 2014 Oct;32(5):1005-16. doi: 10.1007/s10637-014-0106-5.

16.

Concept and viability of androgen annihilation for advanced prostate cancer.

Mohler JL.

Cancer. 2014 Sep 1;120(17):2628-37. doi: 10.1002/cncr.28675. Review.

17.

The androgen receptor transcriptional program in castration-resistant prostate cancer: cell lines vs. tissue samples.

Roth JE, Peer CJ, Price DK, Figg WD.

Cancer Biol Ther. 2014 Jan;15(1):16-8. doi: 10.4161/cbt.27149.

18.

Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.

Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.

Oncogene. 2014 May 29;33(22):2815-25. doi: 10.1038/onc.2013.235. Review.

19.

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB.

Anticancer Drugs. 2013 Aug;24(7):743-53. doi: 10.1097/CAD.0b013e328361feb0.

20.

PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.

Bluemn EG, Spencer ES, Mecham B, Gordon RR, Coleman I, Lewinshtein D, Mostaghel E, Zhang X, Annis J, Grandori C, Porter C, Nelson PS.

Mol Cancer Res. 2013 Jun;11(6):568-78. doi: 10.1158/1541-7786.MCR-12-0710.

Supplemental Content

Support Center